Controlled release of methotrexate from W/O microemulsion and its in vitro antitumor activity

Basit Öğe Kaydı
dc.contributor.authorKarasulu H.Y.
dc.contributor.authorKarabulut B.
dc.contributor.authorGöker E.
dc.contributor.authorGüneri T.
dc.contributor.authorGabor F.
dc.date.accessioned2019-10-26T23:59:38Z
dc.date.available2019-10-26T23:59:38Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractThe objective of this study was to prepare the microemulsion of methotrexate (M-MTX) for oral use and to investigate the suppressive effect of MTX-loaded microemulsion on MCF-7 human breast cancer cells. At the same time this effect of M-MTX was compared with those of a solution of the drug (Sol-MTX). Microemulsion was composed of soybean oil as oil phase, a mixture of Cremophore EL and Span 80 as surfactants, and isopropyl alcohol as co-surfactant, and 0.2 N NaOH as the aqueous phase. MTX was added into microemulsion at the last stage. We clearly demonstrated that M-MTX had a significant cytotoxic effect on breast cancer cell lines and the cytotoxic effect of M-MTX was significantly more than that of solutions (p < 0.05) and IC50 value for M-MTX was 40 ng/mL. We also examined M-MTX and Sol-MTX on a model biological environmental model. For this purpose a gastrointestinal cell culture model, the Caco-2 cell line, was used to investigate the cytotoxic effects of the polymeric carrier and its effect on the cell monolayer integrity. The differences between the viability of cells for M-MTX and Sol-MTX were significantly different when applied to ANOVA according to 2 x 8 factorial randomized design (p:0.016; for ?: 0.05, power : 0.695). According to the in vitro cytotoxicity studies, we concluded that when MTX was incorporated into the microemulsion (M-MTX), which is a new drug carrier system, it suppresses tumour cell growth on multiple tumor lines. These results indicate that M-MTX may exert a low cytotoxic effect on normal cells and may be effective as an antitumor agent that induces apoptosis. Copyright © Informa Healthcare.en_US
dc.identifier.doi10.1080/10717540601067760en_US
dc.identifier.endpage233en_US
dc.identifier.issn1071-7544
dc.identifier.issue4en_US
dc.identifier.pmid17497355en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage225en_US
dc.identifier.urihttps://doi.org/10.1080/10717540601067760
dc.identifier.urihttps://hdl.handle.net/11454/21429
dc.identifier.volume14en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofDrug Deliveryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCaco-2en_US
dc.subjectCytotoxic Effecten_US
dc.subjectMCF-7en_US
dc.subjectMethotrexateen_US
dc.subjectMicroemulsionen_US
dc.subjectStabilityen_US
dc.titleControlled release of methotrexate from W/O microemulsion and its in vitro antitumor activityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu